An immunomodulatory molecular analogue of thalidomide, which has shown promise in phase 2 studies for managing myeloma, and possibly other cancers.
Adverse effects BM suppression with anaemia, thrombocytopaenia, neutropaenia, diarrhoea, fever, muscle cramps, neuropathy, constipation, rash, fatigue.
References in periodicals archive ?
James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid.
Table 26: Ongoing Phase II trial for Actimid in MM, 2007 64
Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra